Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change
08/07/26	€0.3350	-1.76%
07/07/26	€0.3410	-1.16%
06/07/26	€0.3450	+2.99%
03/07/26	€0.3350	+1.21%
02/07/26	€0.3310	0.00%

Delayed Quote Börse Stuttgart

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3895EUR

Average target price

1.000EUR

Spread / Average Target

+156.74%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Börse Stuttgart Other stock markets 20:48:11 08/07/2026 +04			5-day change	1st Jan Change
0.3350 ^EUR	-1.76%		+5.83%	+25.00%

07-01	Nicox Submits NCX 470 New Drug Application In The United States	CI
07-01	Nicox files U.S. marketing approval application

Market Cap	34.33M 39.14M 31.69M 29.29M 55.51M 3.75B 56.62M 381M 148M 1.83B 147M 144M 6.37B	P/E 2026 *	-5.56x	P/E 2027 *	39x
Enterprise Value	34.33M 39.14M 31.69M 29.29M 55.51M 3.75B 56.62M 381M 148M 1.83B 147M 144M 6.37B	EV / Sales 2026 *	11.4x	EV / Sales 2027 *	3.43x
Free-Float	99.65%	Yield 2026 *	-	Yield 2027 *	-

07-01	Nicox Submits NCX 470 New Drug Application In The United States	CI
07-01	Nicox files U.S. marketing approval application
06-23	Nicox Bags EUR6 Million Shareholder Loan	MT
06-23	Nicox Secures Backing From a Shareholder and Financial Partner
06-18	Nicox Receives Positive Feedback from China
06-18	Nicox Announces Positive Pre-Submission Regulatory Feedback in China Supporting NDA Filing for NCX 470	CI
04-30	Nicox S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-24	Nicox SA Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting	CI
02-24	Edenred, Forvia, Freelance.com... Key Stocks to Watch Today in Paris -
02-24	Nicox Reports Positive Phase 3 Results for NCX 470
02-16	Nicox, Sanofi, Valneva... Stocks to Watch Today in Paris
02-16	Nicox Moves Forward with U.S. Health Authorities for Its NCX 470
01-05	Nicox Strengthens Its Financial Position

07-01	Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment	GL
06-23	Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company	GL
06-18	Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470	GL
06-08	Reminder: Nicox June 2024 Warrants will expire June 19, 2026	GL
06-03	Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative	GL

Nicox SA Stock Börse Stuttgart

Stocks

NXOA

FR0013018124

Pharmaceuticals

Valuation: Nicox SA

Chart: Nicox SA

Latest news : Nicox SA

Press Releases: Nicox SA

News in other languages: Nicox SA

Quotes and Performance

Course Extremes

Managers and Directors: Nicox SA

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

07-01	Bourse : Schneider se renforce dans l'IA, Air Liquide investit pour SK Hynix, Nike déçoit
07-01	Nicox dépose une demande d'autorisation de mise sur le marché aux Etats-Unis
07-01	La Bourse s'habitue à tout
07-01	Nicox : Demande d’autorisation de mise sur le marché de NCX 470 soumise aux Etats-Unis par Kowa, avec un paiement d’étape de 3 millions d’euros associé
06-23	Bourse : Sanofi enchaîne les AMM, Prysmian enchaîne les contrats, l'IA enchaîne les dépenses

1 week	+4.12%
Current month	+4.12%
1 month	+5.25%
3 months	-6.06%
6 months	+9.12%
Current year	+23.55%

1 week	0.3	0.4
1 month	0.27	0.4
3 years	0.11	0.7
5 years	0.11	3.81
10 years	0.11	13.56

Manager	Title	Age	Since
Gavin Spencer CEO	Chief Executive Officer	55	28/02/2024
Sandrine Gestin DFI	Director of Finance/CFO	58	01/01/2015
Doug Hubatsch CTO	Chief Tech/Sci/R&D Officer	-	13/12/2021

Director	Title	Age	Since
Gavin Spencer BRD	Director/Board Member	55	08/04/2024
Damian Marron CHM	Chairman	64	16/07/2024
Marc Bozec BRD	Director/Board Member	-	16/07/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NICOX SA	-1.76%	+5.83%	+55.00%	-24.89%	39.23M
MERCK & CO., INC.	-2.42%	-0.02%	+54.05%	+14.00%	318B
MERCK KGAA	-1.83%	-3.70%	+24.69%	-4.59%	70.43B
HALOZYME THERAPEUTICS, INC.	-3.13%	+2.77%	+41.84%	+112.07%	9.68B
KYOWA KIRIN CO., LTD.	-1.29%	+3.58%	+7.01%	+2.10%	8.78B
SK BIOPHARMACEUTICALS CO., LTD.	-3.30%	-5.20%	-11.15%	+8.89%	4.39B
BETTA PHARMACEUTICALS CO., LTD.	-4.32%	-4.72%	+10.28%	+19.21%	4.01B
YUHAN CORPORATION	-1.71%	-1.57%	-35.78%	+27.96%	3.46B
SUPERNUS PHARMACEUTICALS, INC.	+0.16%	+1.17%	+49.47%	+60.79%	2.78B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-3.49%	-2.87%	+11.25%	-24.63%	2.16B
Average	-2.37%	-1.46%	+20.67%	+19.09%	47.1B
Weighted average by Cap.	-2.34%	-2.03%	+45.85%	+13.12%

	2026 *	2027 *
Net sales	3M 3.42M 2.77M 2.56M 4.85M 328M 4.95M 33.3M 12.94M 160M 12.84M 12.56M 556M	10M 11.4M 9.23M 8.53M 16.17M 1.09B 16.49M 111M 43.12M 534M 42.81M 41.88M 1.85B
Net income	-6M -6.84M -5.54M -5.12M -9.7M -655M -9.9M -66.59M -25.87M -321M -25.69M -25.13M -1.11B	1M 1.14M 923K 853K 1.62M 109M 1.65M 11.1M 4.31M 53.42M 4.28M 4.19M 185M
Net Debt	-	-